Tokyo, Japan – 22 December 2016: Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565) reports that Novartis announced that it has signed a licensing agreement with Sunovion Pharmaceuticals Inc. (MARLBOROUGH, Mass, hereafter ‘Sunovion’) for the US commercial rights to its three treatments for chronic obstructive pulmonary disease (COPD), Utibron™ Neohaler® (indacaterol/glycopyrrolate) inhalation powder, Seebri™ Neohaler® (glycopyrrolate) inhalation powder, and Arcapta® Neohaler® (indacaterol) inhalation powder.
This deal is specific to the US only and has no implications outside this market. Novartis will continue to manufacture these medicines for Sunovion. Novartis will also continue to bring Ultibro® Breezhaler® (indacaterol/glycopyrronium), Seebri® Breezhaler® (glycopyrronium) and Onbrez® Breezhaler® (indacaterol) to patients living with COPD outside of the US.
Peter Bains, Chief Executive Officer at Sosei commented: “We are very pleased that, with the announcement of Novartis working with Sunovion, Utibron™ Neohaler® and Seebri™ Neohaler® will soon be made available to patients in the US. We are confident that with its established respiratory focus and expertise, Sunovion will be a strong partner for the Novartis respiratory franchise.”
Outside the US, Novartis’ indacaterol/glycopyrronium formulation Ultibro Breezhaler 110/50 mcg administered once-daily is the leading therapy in sales in its class. In all markets other than the US, Novartis has a full respiratory presence and portfolio and is committed to building category leadership and meeting the evolving needs of patients living with respiratory diseases including asthma and COPD. The COPD portfolio remains a global priority for Novartis.